TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
|Articles|September 18, 2012
States Seek a Middle Ground on Medicaid
Advertisement
A handful of states are considering only partially expanding their Medicaid programs under the federal health-care overhaul—a new twist on how states are interpreting the Supreme Court's ruling on the law.
Indiana, New Mexico and Wisconsin are among the states asking the federal government to let them omit from the Medicaid expansion residents whose incomes put them just above the poverty level. The states hope to take advantage of provisions in the Affordable Care Act that offer a federal subsidy to help these residents buy private insurance, starting in 2014.
Read the full story:
Source: The Wall Street Journal
Advertisement
Related to this article
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.
Teva's Weltruza, a once-monthly subcutaneous olanzapine injection, requires no loading doses, oral supplementation, or postinjection monitoring.
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
3
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
4
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
5